KRAS and non-small cell lung carcinoma: Phase III of the CodeBreaK200 trial evaluated the efficacy of sotorasib vs. docetaxel in patients with KRAS-mutated NSCLC who had previously been treated with platinum-based chemotherapy and checkpoint inhibitors and progressed on the treatment.